Published in Am J Pediatr Hematol Oncol on January 01, 1986
Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood (2011) 1.88
Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther (2010) 1.15
Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia (2012) 1.10
The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations. Clin Exp Med (2009) 1.02
Pharmacogenomics in pediatric leukemia. Curr Opin Pediatr (2010) 0.93
Dual-porosity hollow nanoparticles for the immunoprotection and delivery of nonhuman enzymes. Nano Lett (2014) 0.87
Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia. Clin Med Insights Oncol (2014) 0.87
First-line treatment of acute lymphoblastic leukemia with pegasparaginase. Biologics (2009) 0.83
Immunoproteome analysis of soluble and membrane proteins of Shigella flexneri 2457T. World J Gastroenterol (2006) 0.81
Effect of premedications in a murine model of asparaginase hypersensitivity. J Pharmacol Exp Ther (2015) 0.79
Development of an ELISA to detect circulating anti-asparaginase antibodies in dogs with lymphoid neoplasia treated with Escherichia coli l-asparaginase. Vet Comp Oncol (2012) 0.78
The periplasmic enzyme, AnsB, of Shigella flexneri modulates bacterial adherence to host epithelial cells. PLoS One (2014) 0.75
L-Asparaginase Activity in Cell Lysates and Culture Media of Halophilic Bacterial Isolates. Iran J Pharm Res (2016) 0.75
L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. J Pharmacol Pharmacother (2016) 0.75
Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol (1987) 2.81
Preferential amplification of the paternal allele of the N-myc gene in human neuroblastomas. Nat Genet (1993) 2.72
Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol (1996) 2.59
Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. Cancer Res (2001) 2.48
Successful bone-marrow transplantation for infantile malignant osteopetrosis. N Engl J Med (1980) 1.95
Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol (1993) 1.79
Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res (1985) 1.78
Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res (1990) 1.69
Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol (2001) 1.64
Small molecule nerve growth factor analogs image receptors in vivo. Nat Biotechnol (1996) 1.56
Is more better? Dose intensity in neuroblastoma. J Clin Oncol (1991) 1.51
Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. J Clin Oncol (1993) 1.49
Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci U S A (1998) 1.48
Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: a report from the Childrens Cancer Group. J Clin Oncol (1994) 1.45
Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia. Blood (1986) 1.42
Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-kettering Cancer Center Experience and A Literature Review. Cancer (2001) 1.41
Cyclophosphamide versus ifosfamide in paediatric oncology. Lancet (1990) 1.39
Successful treatment of severe aplastic anemia by bone marrow transplantation from HLA nonidentical family members: preliminary results utilizing cyclophosphamide and 600 cGY fractionated total body irradiation. Am J Pediatr Hematol Oncol (1991) 1.39
An assessment of monocyte procoagulant activity in patients with solid tumors. J Surg Res (1987) 1.37
Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer (1995) 1.36
Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma. Proc Natl Acad Sci U S A (2000) 1.33
Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice. J Natl Cancer Inst (1986) 1.31
Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med (1998) 1.30
Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors. Proc Natl Acad Sci U S A (2000) 1.29
Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol (1994) 1.26
GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood (1989) 1.25
Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res (2001) 1.18
Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol (1996) 1.18
Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol (2001) 1.16
Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res (1998) 1.16
Synovial sarcoma mimicking desmoplastic small round-cell tumor: critical role for molecular diagnosis. Med Pediatr Oncol (1999) 1.14
Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer (1992) 1.12
Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma. Clin Cancer Res (2001) 1.11
Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol (2001) 1.10
Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: method for purging autologous bone marrow. Cancer Res (1985) 1.10
Cost effectiveness analysis of intravenous ketorolac and morphine for treating pain after limb injury: double blind randomised controlled trial. BMJ (2000) 1.09
Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res (1987) 1.08
Infectious mononucleosis prior to acute leukemia: a possible role for the Epstein-Barr virus. Cancer (1972) 1.05
Immune suppression in vivo with antigen-modified syngeneic cells. I. T-cell-mediated suppression to the terpolymer poly-(Glu, Lys, Phe)n. J Exp Med (1978) 1.03
Genetic heterogeneity and clonal evolution in neuroblastoma. Br J Cancer (2001) 1.02
Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review. J Clin Oncol (1998) 1.02
High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. J Clin Oncol (1998) 1.01
The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood (1996) 1.01
Autonomous production of parathyroid hormone by lymphoblastic leukemia cells in culture. J Pediatr (1979) 1.01
Acute hemorrhage into Wilms tumor: a cause of rapidly developing abdominal mass with hypertension, anemia, and fever. J Pediatr (1977) 1.01
The nature of childhood leukemia and lymphoma. Am J Pathol (1978) 1.00
B and T cell lymphomas. Analysis of blood and lymph nodes in 87 patients. Am J Med (1975) 1.00
Stage 4 neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome. J Pediatr Surg (1994) 1.00
Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Res (1987) 0.99
Role of low-affinity Fc receptors in antibody-dependent tumor cell phagocytosis by human monocyte-derived macrophages. Cancer Res (1991) 0.99
Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Med Phys (1991) 0.99
Do trauma teams make a difference? A single centre registry study. Resuscitation (2007) 0.99
Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers. Clin Cancer Res (1998) 0.98
Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies. J Clin Oncol (1986) 0.98
Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR. Clin Cancer Res (2001) 0.98
Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplant (2001) 0.97
Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell. Biochem Biophys Res Commun (1985) 0.97
Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p. J Mol Diagn (2000) 0.97
Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors. Cancer Immunol Immunother (2000) 0.96
Effects of parenteral recombinant human macrophage colony-stimulating factor on monocyte number, phenotype, and antitumor cytotoxicity in nonhuman primates. Blood (1990) 0.96
CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma. Cancer Res (2000) 0.96
Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. J Clin Oncol (1983) 0.95
Pharmacokinetics of IgG and IgM anti-ganglioside antibodies in rats and monkeys after intrathecal administration. J Pharmacol Exp Ther (1998) 0.95
Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma. Clin Cancer Res (1998) 0.94
Sclerodermatous graft-versus-host disease limited to an area of measles exanthem. Lancet (1978) 0.94
Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Childrens Cancer Study Group. J Clin Oncol (1991) 0.94
GD2 oligosaccharide: target for cytotoxic T lymphocytes. J Exp Med (1995) 0.93
Fatal veno-occlusive disease of the liver following high dose chemotherapy, irradiation and bone marrow transplantation. Am J Med (1980) 0.93
Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report. J Clin Oncol (1993) 0.93
Bicycle related injuries presenting to a trauma centre in Hong Kong. Injury (2009) 0.93
Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma. Clin Cancer Res (1997) 0.93
Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities. J Nucl Med (1991) 0.92
Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. J Clin Oncol (1989) 0.92
Prognostic significance of surface marker analysis in childhood non-Hodgkin's lymphoproliferative malifnancies. Am J Hematol (1976) 0.90
Lymphocytes bearing receptors for both sheep erythrocytes and complement in patients with neoplastic and non-neoplastic diseases. Clin Immunol Immunopathol (1977) 0.90
Pyogenic liver abscess. Am Surg (1978) 0.90
Low numbers of CSF blasts at diagnosis do not predict for the development of CNS leukemia in children with intermediate-risk acute lymphoblastic leukemia: a Childrens Cancer Group report. J Clin Oncol (1994) 0.89
High risk trauma in older adults in Hong Kong: a multicentre study. Injury (2008) 0.89
Development of a method to measure kinetics of radiolabelled monoclonal antibody in human tumour with applications to microdosimetry: positron emission tomography studies of iodine-124 labelled 3F8 monoclonal antibody in glioma. Eur J Nucl Med (1993) 0.89
Allogeneic transplantation of blood-derived, T cell-depleted hemopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. Bone Marrow Transplant (1989) 0.89
Total lymphoid irradiation and cyclophosphamide as preparation for bone marrow transplantation in severe aplastic anemia. Blood (1980) 0.89
Childhood leukemia-lymphoma. Heterogeneity of phenotypes and prognoses. Am J Clin Pathol (1979) 0.89
Immune suppression in vivo with antigen-modified syngeneic cells. II. T cell-mediated nonresponsiveness to fowl gamma-globulin. J Immunol (1979) 0.88
Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor. J Exp Med (1990) 0.88
Disease-specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double-blind, controlled trial. JPEN J Parenter Enteral Nutr (1985) 0.88
Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Med Pediatr Oncol (2000) 0.87
Transient blueberry muffin appearance of a newborn with congenital monoblastic leukemia. J Am Acad Dermatol (1989) 0.87
Oral etoposide for refractory and relapsed neuroblastoma. J Clin Oncol (1999) 0.86
Oncornavirus-like particles from cultured bone marrow cells preceding leukemia and malignant histiocytosis. Proc Natl Acad Sci U S A (1975) 0.86
Malignant osteopetrosis: a disease of abnormal osteoclast proliferation. Metab Bone Dis Relat Res (1981) 0.86
Renal and metabolic complications of childhood non-Hodgkin's lymphoma. Semin Oncol (1977) 0.86
Oral calcium treatment in vitamin D-dependent rickets type II. J Paediatr Child Health (1994) 0.85
GD2 synthase: a new molecular marker for detecting neuroblastoma. Cancer (2001) 0.85